ArticleFuture oncology (London, England)2025

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.

Kim Nguyen Chi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.